Description
VOXZOGO®(vosoritide), a CNP analog, has been developed for the treatment of children with ACH. In animal ACH models, endogenous CNP overproduction and continuous intravenous infusion of exogenous CNP rescues impaired bone growth and increases long bone growth. Vosoritide safety profile and efficacy have been investigated in a Phase II, open-label, dose-escalation and extension study, and a double-blind, placebo-controlled, Phase III study.
EU-VOX-00455 05/22
Download
References:
Chan ML, Qi Y, Larimore K, Cherukuri A, Seid L, Jayaram K, Jeha G, Fisheleva E, Day J, Huntsman-Labed A, Savarirayan R, Irving M, Bacino CA, Hoover-Fong J, Ozono K, Mohnike K, Wilcox WRR, Horton WA, Henshaw J Clin Pharmacokinet 2022;61:263–80 doi: 10.1007/s40262-021-01059-1